Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol

Abstract Background Neoadjuvant chemotherapy is used in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) to increase resection rate and improve cancer outcome. However, there is a need for better prediction of resectability. The aim of this prospective, si...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Luís Filipe Abreu de Carvalho, Filip Gryspeerdt, Wim Ceelen, Karen Geboes, Suzane Ribeiro, Anne Hoorens, Nele Vandenbussche, Kathleen B.M. Claes, Clarisse Lecluyse, Aliaksandr Anisau, Johan Van Ongeval, Willem Lybaert, Lars Triest, Andrew Vervaecke, Steven Sas, Barbara Claerhout, Carolien Beyls, Mark Sie, Frederik Berrevoet
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-05-01
Serie:	BMC Surgery
Soggetti:	Pancreatic cancer Borderline resectable pancreatic cancer Locally advanced pancreatic cancer Neoadjuvant chemotherapy FOLFIRINOX Liquid biopsy
Accesso online:	https://doi.org/10.1186/s12893-025-02938-1
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!